China Acetylcholinesterase Inhibitor Donepezil for Dementia Treatment 120014-06-4, Find details about China Donepezil, 120014-06-4 from Acetylcholinesterase Inhibitor Donepezil for Dementia Treatment 120014-06-4
Product Name:DONEPEZIL HYDROCHLORIDE
Synonyms:AKOS 226-31;E-2020;DONEPEZIL HCL;ARICEPT;DonepezilHcl120011-70-3/;DONEPEZIL (DONEPEZIL HYDROCHLORIDE);2-[(1-Benzyl-4-piperidyl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one hydrochloride;Donepezil hydrochloride
CAS:110119-84-1
MF:C24H30ClNO3
MW:415.95
Description
Donepezil is a centrally acting reversible acetylcholinesterase inhibitor. Its main therapeutic use is in the palliative treatment of Alzheimer's disease. Common side effects include gastrointestinal upset. It has an oral bioavailability of 100% and easily crosses the blood-brain barrier. Because it has a biological half-life of about 70 hours, it can be taken once a day.
Donepezil has been tested in other cognitive disorders (and is sometimes used off label) including Lewy body dementia and vascular dementia, but it is not currently approved for these indications. Donepezil has been found to improve sleep apnea in Alzheimer's patients. Donepezil has also been studied in patients with Mild Cognitive Impairment, schizophrenia, attention deficit disorder, post-coronary bypass cognitive impairment, cognitive impairment associated with multiple sclerosis, CADASIL, and Down syndrome.
COA
TEST ITEM | SPECIFICATION | RESULT |
Appearance | Off white to white crystalline powder | Complies |
Solubility | freely Freely soluble in chloroform, soluble in water and Acetic acid, slightly soluble in Acetonitrile and ethanol, insoluble in Ethylacetoacetate and n-hexane | Complies |
Identification | (1)By IR absorption ,To match with working standard | Complies |
(2) The retention time of the major peak of the sample should accord with that of the working standard. | Complies | |
(3) Test for chlorides. Reponds to the test for Chlorides. | Complies | |
PH | 4.0-7.0 | 6.10 |
Residue on ignition | ≤0.1% | 0.03% |
Related substance | Any Unkonwn single impurity≤0.3% Total ≤0.5% | 0.04% 0.18% |
Heavy metal | ≤10ppm | <10ppm |
Residual Solvents | Methanol≤0.3% Ethanol≤0.5% Ethyl acetate≤0.5% Toluene≤0.089% Acetic acid≤0.5% | Not detected Not detected Not detected Not detected Not detected |
Loss on drying | ≤0.5% | 0.20% |
Assay | On dried base, C24H29NO3·HCl should be 98.0% to 102.0% | 100.20% |
Conclusion: The product complies to Enterprise standard |
Usage | A nootropic. An inhibitor of acetylcholinesterase |
Usage | A labelled nootropic. An inhibitor of acetylcholinesterase. |
Usage | Antialzheimer |
Usage | Labeled Donepezil, intended for use as an internal standard for the quantification of Donepezilby GC- or LC-mass spectrometry. |
Definition | ChEBI: Donepezil hydrochloride is a centrally acting reversible acetyl cholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine. |